The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Open accessAbstract
Cancer therapy by entrapment: Mutations in the KRAS oncogene occur at high frequency in several of the most lethal human cancers, including lung and pancreatic cancer. Substantial effort has thus been directed toward developing KRAS inhibitors. KRAS encodes an enzyme that binds the nucleotide GTP and hydrolyzes it to GDP. It had been thought that oncogenic mutations disable this hydrolytic activity, locking KRAS in the GTP-bound, active state. Surprisingly, Lito et al. found that a certain KRAS mutant (G12C) retains hydrolytic activity and continues to cycle between its active and inactive states. They describe a compound that inhibits KRAS(G12C) signaling and tumor cell growth by binding to the GDPbound form of KRAS, trapping it in its inactive state. Science , this issue p. 604
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“early preclinical studies with KRASG12C inhibitors, such as ARS-1620, have suggested a potential role for adaptive feedback as a mechanism of resistance (7) (15).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, as described by Lito et al, increased RTK activity may lead to increased cycling of KRASG12C to its active GTP-bound form that hinders the binding of most KRASG12C inhibitors, which bind specifically to the inactive GDP-bound form (7).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“compounds have been identified that bind covalently to cysteine 12 within the switch II pocket of the GDP-bound form of the KRASG12C protein, preventing oncogenic signaling and causing potent tumor regressions in preclinical models.3-7”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the appreciable degree of nucleotide cycling observed in KRAS G12C -mutant protein proved critical for the development of clinically active KRAS G12C -selective inhibitors which bind the GDP-bound conformation and lock KRAS in the inactive state [7-9].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition12,15.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [15]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“The inhibitors function by locking KRASG12C in an inactive GDP bound state, exploiting the unique property of KRASG12C to cycle between the GDP- and GTP-bound states (6,7).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These resistance mutations probably increase the fraction of KRAS protein in the active GTP-bound form that does not bind to the drug.4”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition12,15.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Given this particular feature of the KRAS G12C mutant protein, the efficacy of these compounds can be increased by concomitant receptor tyrosine kinase (RTK) inhibition that further maintain KRAS G12C in a GDP-bound conformation, facilitating the binding of the covalent inhibitor(7-9).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that RTK inhibition in NSCLC preclinical models can potentiate KRAS G12C covalent inhibitors, by slowing down exchange factors favoring a GDP-bound status of KRAS(8).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [8]
In the citing paper
“ARS-853 was firstly selected as a potent inhibitor that suppresses K-RasG12C-dependent cell proliferation.4,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“The binding of these compounds to K-RasG12C induces structurally disordered switch I/II, which converts the GTP preference of naive K-RasG12C to GDP.”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“However, it failed to demonstrate in vivo efficacy due to undesirable pharmacokinetics.4,5,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Consequently, a large fraction of K-RasG12C protein is trapped in the inactive GDP-bound state, which impairs its interaction with downstream effectors, such as rapidly accelerated fibrosarcoma kinase (RAF).3,4,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“For example, secondary KRAS mutations would confer intrinsic resistance to ARS-853 in KRASG12C mutant models by either potentiating nucleotide exchange (secondary mutation: Y40A, N116H, or A146V) or impairing inherent GTPase activity (secondary mutation: A59G, Q61L, or Y64A) (Figure 3D).49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Instead, K-RasG12C inhibitors act primarily through targeting MAPK/ERK pathway for growth inhibition.4, 5, 6, 7,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“These preclinical findings strongly imply that intrinsic resistance might be accountable for the heterogeneous responses to K-RasG12C inhibition in the clinic.4, 5, 6, 7,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“In most KRASG12C mutant models, the phosphorylation status of AKT and mTORC1-effector ribosomal protein S6 is barely affected by K-RasG12C inhibition.6,7,12,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“In line with the these findings, inconsistent results were observed co-treating KRASG12C mutant cancer cells with K-RasG12C inhibitors plus either MEK or ERK inhibitors, limiting the use of these drug combinations in the clinic.6,12,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Lito et al.49 reported that the effect of ARS-853 was potentiated by EGFR inhibition in H2122 and Calu-1 cells.”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [65]
In the citing paper
“Accordingly, inhibitors of this type are KRASG12C specific; therefore, they do not affect RAS signalling in non-malignant cells65,70–72 and, at least theoretically, have a low risk of on-target, off-tumour toxicities.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [65]
In the citing paper
“KRASG12C is not permanently GTP-bound and maintains a dependency on upstream receptor tyrosine kinase (RTK) signaling for GEF-mediated GTP reloading (9, 10).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [9]
In the citing paper
“The rationale for pursuing SHP2 and SOS1 inhibitors as pan-KRAS inhibitors is grounded in the evidence that several (K)RAS oncoproteins, including KRASG12C, still cycle between an inactive and active state and rely on upstream activation and nucleotide exchange to exhibit their full transforming potential (9–13, 33, 34).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [9]
In the citing paper
“G12C-Is bind an evanescent pocket in KRAS-GDP, positioning a reactive group to couple to the mutant cysteine.”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Lito et al., 2016
In the citing paper
“follow-up studies indicated that these initial compounds showed only limited potency (39, 40).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [39]
In the citing paper
“Binding of compound 12 to the switch II pocket impaired KRAS signalling by shifting nucleotide affinity from favouring GTP to GDP and led to the accumulation of KRAS in its inactive state91.”
From Advances in covalent drug discovery (2022) · cites this paper as [91]
In the citing paper
“Still, the mutant KRAS undergoes GDP–GTP cycling [5].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Research works printed but not linked: 1
- 10.1128/MCB.8.6.2472 · DOI
Cited by
Sorted by citations
Items 501–600 of 700
IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells
Rodrigues, F. S., Miranda, V. S., Carneiro-Lobo, T., Scalabrini, L. C., Kruspig, B., Levantini, E., Murphy, D. J., & Bassères, D. S. D. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165806 · Cited by 5
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 5
Basket Trials: Past, Present, and Future
Murciano‐Goroff, Y. R., Uppal, M., Chen, M. F., Harada, G., & Schram, A. M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-012927 · Cited by 6
Synergy and anti‐cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS‐RGL1
Hacisuleyman, A., & Erman, B. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26657 · Cited by 5
Tsukamoto, S., Huaze, Y., Weisheng, Z., Machinaga, A., Kakiuchi, N., Ogawa, S., Seno, H., Higashiyama, S., Matsuda, M., & Hiratsuka, T. (2024) · Cancer Science · doi:10.1111/cas.16439 · Cited by 5
Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
Ren, B., 高卓维, Zheng, K., Yang, Y., Su, P., Luo, Q., Feng, J., Zhentao, L., Geng, Y., Ju, Y., et al. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11942 · Cited by 6
KRAS Oncoprotein Signaling in Cancer
Lito, P. (2025) · New England Journal of Medicine · doi:10.1056/nejmcibr2408099 · Cited by 6
Self-citationAlawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., Moore, J., Maddern, G., Roder, D., Smith, A., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00856-9 · Cited by 5
Sun, T., Zuo, T., Hui, P., & Cai, G. (2022) · Cancer Cytopathology · doi:10.1002/cncy.22579 · Cited by 5
Strohbehn, G. W., Sankar, K. N., Qin, A., & Kalemkerian, G. P. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2134777 · Cited by 5
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 6
Zhang, J., Zhang, J., Leung, E. L., & Yao, X. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178419 · Cited by 5
Germline variation in RASAL2 may predict survival in patients with RAS ‐activated colorectal cancer
Wills, C., Watts, K., Maughan, T., Fisher, D. J., Tassan, N. A. A., Houlston, R. S., Escott‐Price, V., & Cheadle, J. P. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23133 · Cited by 5
Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma
Przywara, G., Biegańska, O., Biczak, E., Białoń, A., Fidorowicz, D., Dankowska, A., Łapińska, Z., & Kulbacka, J. (2025) · Cells · doi:10.3390/cells14161232 · Cited by 5
Carta, L., Hutcheson, R., Bigarella, C. L., Zhang, S., Davis, S. A., Rudolph, M. J., Reynolds, C. H., Quick, M., Williams, T. M., Schmertzler, M., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0618 · Cited by 4
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 5
Genetically encodable biosensors for Ras activity
Weeks, R., Mehta, S., & Zhang, J. (2024) · RSC Chemical Biology · doi:10.1039/d3cb00185g · Cited by 5
p38 mitogen-activated protein kinase inhibitors
El‐Damasy, A. K., Salem, M. S. H., Sebaiy, M. M., & Elgawish, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00011-5 · Cited by 4
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies
Vanclooster, P., Seghers, S., & Prenen, H. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001042 · Cited by 5
Lansbergen, M. F., Dings, M. P. G., Köster, J., Labots, M., Kerver, E. D., Jochems, A., Homs, M. Y. V., de Vos‐Geelen, J., Hendriks, M. P., Tanck, M. W. T., et al. (2025) · Med · doi:10.1016/j.medj.2025.100601 · Cited by 5
Carlisle, J. W., & Harvey, R. D. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320667 · Cited by 4
Ferrara, M. G., Stefani, A., Pilotto, S., Carbone, C., Vita, E., Salvatore, M. D., D’Argento, E., Sparagna, I., Monaca, F., Valente, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.792385 · Cited by 4
Putting the brakes on KRAS-G12C nucleotide cycling
Shipman, L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.13 · Cited by 4
A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background
Budagyan, K., & Chernoff, J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_20 · Cited by 4
Analysis of RAS as a tumor suppressorPreprint
Kenney, C., & Stites, E. C. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/153692 · Cited by 3
McAndrews, K. M., Mahadevan, K. K., Li, B., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., Lyu, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.29.635543 · Cited by 4
Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase
Eliseev, I. A., Shkil, D. O., Shumakova, V. S., Chernyshov, V. V., Balakin, K. V., & Ivanov, R. A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673372217250515031136 · Cited by 3
Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1
Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Yu, Z., Wu, C., Wu, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.031 · Cited by 4
Chatterjee, A., Ali, M. K. M., Bailey, C. M., Liu, Y., Small, D., Smith, C. C., Traer, E. A., Wang, Y., Silvestri, G., & Baer, M. R. (2026) · Leukemia · doi:10.1038/s41375-026-02982-7 · Cited by 2
Optimization of Covalent Warhead Trajectory for KRAS G12C Active-State Inhibition
Condakes, M. L., Civiello, R. L., Lakkaraju, S. K., Sloane, J. L., Chourb, L. S., Downes, D. P., Drexler, D. M., Dzhekieva, L., El-Samin, M., Levins, C. G., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03306 · Cited by 4
Olmo-González, D., Zhou, M., Oliveira, N. G., Zhou, F., Yan, F., González, J., València-Clua, K., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02998-z · Cited by 3
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 3
Kato, R., Solanki, H. S., Özakıncı, H., Desai, B., Gundlapalli, H., Yang, Y. C., Aronchik, I., Singh, M., Johnson, J., Marusyk, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3714 · Cited by 3
KRAS: Structure, function, and development of anticancer drugs
Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 3
Lei, G., & Gan, B. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212166 · Cited by 3
Liu, D., Chen, T., Yu, K., Li, J., Wang, S., Ma, X., Zhu, Q., Ning, Y., & Wang, Y. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03367-8 · Cited by 3
Plasmablastic lymphoma: from genetics to treatment
Frontzek, F., Hailfinger, S., & Lenz, G. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2162341 · Cited by 3
Yang, W., Ge, J., Yuan, M., Li, J., Pan, L., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001428 · Cited by 3
Wu, L., Jiang, W., Liu, Z., Zhang, Y., Qian, J., Liu, Y., Huang, Y.-Y., Li, K., Li, Z., Ma, G.-W., et al. (2023) · Discover Oncology · doi:10.1007/s12672-023-00698-z · Cited by 4
Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors
Tripathi, P., Kumari, R., & Pathak, R. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2023.11.004 · Cited by 3
Dyba, M. D., Denson, J.-P., & Maciag, A. E. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_11 · Cited by 3
Therapeutic Targeting of RAS Mutant Cancers
Stites, E. C., Paskvan, K. V., & Kato, S. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009064828 · Cited by 2
Hikita, E., Gando, Y., Chubachi, H., Shirota, M., Kushiyama, A., & Yasu, T. (2023) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01043 · Cited by 3
Arresting kinase suppressor of Ras in an inactive state
Badshah, S. L., & Mabkhot, Y. N. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0181-z · Cited by 3
Filling in the GAPs in understanding RAS
Cox, A. D., & Der, C. J. (2021) · Science · doi:10.1126/science.abl3639 · Cited by 3
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875.1 · Cited by 3
Sorbara, M., & Béry, N. (2021) · Biochemical Society Transactions · doi:10.1042/bst20201059 · Cited by 2
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Bostancioglu, S. M., & Acar, A. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07137-y · Cited by 2
McDonald, R. A., Varela-Ramı́rez, A., & Ashley, A. K. (2025) · Biology · doi:10.3390/biology14080936 · Cited by 2
Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics
Farooq, M., & Pishvaian, M. J. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.08.004 · Cited by 2
Functional Analysis of Rare RAS Variants of Unknown Significance
Park, S., Ikegami, M., Kitada, R., Takamochi, K., Suzuki, K., Mano, H., & Kohsaka, S. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0188 · Cited by 3
Liang, X., Liu, Y., Zhu, Y., Zhao, Y., Ye, F., Gao, F., Shi, Y., & Guan, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70484 · Cited by 2
Park, K. R., Le, M.-X., Sul, O., Jeon, J., Kwon, M. S., Lee, H., Won, S. H., Kwon, H. N., Cho, W. J., & Park, J. W. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118772 · Cited by 2
Liu, S., Shi, J., Li, H., Li, J., Zhu, Y., Li, B., & Sun, Y. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2021.12.007 · Cited by 2
Guo, Y., Jin, Y., Gao, J., Wang, D., Wang, Y., Shan, L., Yang, M., Li, X., & Ma, K. (2024) · Pharmaceuticals · doi:10.3390/ph17121696 · Cited by 2
ELOVL6 activity attenuation induces mutant KRAS degradation
Hu, X., Atwal, R. S., Xiao, S., Ahmed, S. U., Wang, Z., Zhao, C., Wang, H., & Kelley, S. O. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01998-x · Cited by 5
Cancer Genomic and Epigenomic Variations in Sub-Saharan Africa
Adedeji, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-52554-9_2 · Cited by 2
Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
Moll, H. P., & Casanova, E. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1513724 · Cited by 2
Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity MeasurementsPreprint
Carta, L., Hutcheson, R., Davis, S. A., Rudolph, M. J., Reynolds, C. H., Quick, M., Williams, T. M., Schmertzler, M., & Hadari, Y. R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.27.218248 · Cited by 2
Discovering and targeting dynamic drugging pockets of the oncogene KRAS-G12DPreprint
Hu, Z., & Martı́, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.01.498403 · Cited by 2
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Ralhan, K., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n · Cited by 2
RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitorsPreprint
Baars, B., Orive-Ramos, A., Kou, Z., Gaire, B., Desaunay, M., Adamopoulos, C., Aaronson, S. A., Wang, S., Gavathiotis, E., & Poulikakos, P. I. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.14.638317 · Cited by 2
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerPreprint
Bannoura, S. F., Khan, H. Y., Aboukameel, A., Wan, Y., Bao, B., Uddin, M. H., Jimenez, H., Aboukameel, A., Siddiqui, R., Khan, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.06.692635 · Cited by 2
Targeting KRAS mutation in gastrointestinal cancers
Bicer, F., Akce, M., Piazza, G. A., Foote, J. B., & El‐Rayes, B. F. (2023) · F1000Research · doi:10.12688/f1000research.131688.1 · Cited by 1
Yang, X., Zhang, S., Yang, Y., Duan, X., & Li, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241264853 · Cited by 1
Covalently targeting KRAS G12C
Janes, M. R., Li, L., Hansen, R., Peters, U., Ren, P., & Liu, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00008-5 · Cited by 1
Self-citationHong, C., Lee, J., Kim, D., Hong, S.-J., Park, J., Hong, S., An, K. M., Lee, M., & Han, G. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130087 · Cited by 1
Pakhira, S., Samanta, P., Ghosh, R., Mondal, M., Biswas, S., Sarkar, R., Bhowmik, A., Saha, P., & Hajra, S. (2024) · Journal of Current Oncological Trends · doi:10.4103/jcot.jcot_3_24 · Cited by 1
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Kokori, E., Olatunji, G. D., Ogieuhi, I. J., Ajayi, Y. I., Akinmoju, O. D., Akinboade, A., Irumudomon, J. G., Omoworare, O. T., Ezeano, C., Adebayo, Y. A., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02736-y · Cited by 1
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2
Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer
Wu, L.-H., Yu, R., Yao, M., Rahaman, M. M., & Fang, Z. (2025) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720025500179 · Cited by 1
Gray, J. P., Bildik, G., Kim, H.-N., Sutton, M. N., Wang, J., Osuji, A. O., Batistatou, N., Yang, H., Mao, W., Tan, Z., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113686 · Cited by 1
Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer
Yang, H., Hu, L. T., Su, Z., Peng, F., Wang, Y., Chang, Q., Shen, W., Yang, K., Zhao, J., Guo, L., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114345 · Cited by 1
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been
Cox, A. D., & Der, C. J. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071024-082459 · Cited by 1
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development
Chamseddine, S., Azmi, A. S., & Saif, M. W. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2611395 · Cited by 2
Group Competition Strategy for Covalent Ligand Discovery
Guo, Z., Meng, Y., Zhao, B., Xiao, W., & Wang, C. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c18150 · Cited by 1
GalaxyCDock: Webserver for Covalent Protein–Ligand Binding Mode Prediction
Lee, S., Jung, N., Woo, H., Yang, J., & Seok, C. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169807 · Cited by 1
Time-Resolved Native Mass Spectrometry for Direct Measurement of Biomolecular Kinetics
James, V. K., Stover, L., Bahramimoghaddam, H., Khandelwal, T., Chang, J., Downing, J., Scott, E., Bailey, K. O., Russell, D. H., Baker, L. A., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c21842 · Cited by 1
Leto, S. M., Sassi, F. P., Zanella, E. R., Vurchio, V., Cottino, F., Ferri, M., Damico, A., Grassi, E., Bertotti, A., & Trusolino, L. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08900-0 · Cited by 1
Vitale, A., Marafioti, M., Galassi, T., Madonia, G., Moro, M., & Dubois, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105396 · Cited by 1
Brønsted-basic small molecules activate GTP hydrolysis in KRAS-Q61 mutants
Wang, Y., Chen, S., Cao, Y., Wu, Y., Shi, Z., Wang, C. D., Norinskiy, M. A., Celik, H., & Zhang, Z. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02291-1 · Cited by 2
Mia, M. S., Datta, B. K., Akter, K., Topu, T. K. D., Shawon, J. M., Hossen, F., Pranto, A. R., Shadhin, M. S. T., Tahsin, N., Qahl, S. H., et al. (2026) · The Protein Journal · doi:10.1007/s10930-026-10356-2 · Cited by 1
Clinical sequencing of pancreatic cancer in clinical practice
Hayashi, H. (2018) · Suizo · doi:10.2958/suizo.33.915 · Cited by 1
Molecular Determinants of Gastrointestinal Cancers
Battaglin, F., Randon, G., Raimondi, A., Pagani, F., Arai, H., Pietrantonio, F., & Lenz, H. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.026 · Cited by 1
KRAS-mutated non-small cell lung cancer: new therapy strategies
Лактионов, К. К., Саранцева, К. А., Александровна, Н. Л., Gamayunov, S. V., Kolesnikova, Е. А., & Gordiev, M. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-2-72-81 · Cited by 2
Cregg, J., Edwards, A. V., Tomlinson, A. C. A., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00011-5 · Cited by 3
Precision medicine for colorectal cancer
Hızel, C., Tüzmen, Ş., Amirfallah, A., Calibasi‐Kocal, G., Abbasoğlu, D., Onat, H., Yıldırım, Y., & Baskın, Y. (2018) · CRC Press eBooks · doi:10.1201/9781315154749-5 · Cited by 1
Targeting der kleinen GTPasen über ihre regulatorischen Proteine
Gray, J. L., von Delft, F., & Brennan, P. E. (2019) · Angewandte Chemie · doi:10.1002/ange.201900585 · Cited by 1
Kobayashi, K., Terai, H., Yasuda, H., Hamamoto, J., Hayashi, Y., Takeuchi, O., Mitsuishi, Y., Masuzawa, K., Manabe, T., Ikemura, S., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.110 · Cited by 1
Fang, S.-F., Peng, W., Xiong, Y.-Z., Nie, X., & Huang, J. (2021) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2021-0085 · Cited by 1
Taniguchi, F., Nyuya, A., Toshima, T., Yasui, K., Mori, Y., Okawaki, M., Kishimoto, H., Umeda, Y., Fujiwara, T., Tanioka, H., et al. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0059 · Cited by 1
Oncogenic RAS Signalling Promotes Tumour Immunoresistance by Stabilising PD-L1 mRNA
Coelho, M. (2017) · UCL Discovery (University College London) · Cited by 1
Oncogenic G12D mutation alters local conformations and dynamics of K-RasPreprint
Vatansever, S., Erman, B., & Gumus, Z. H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/178483 · Cited by 1
Ly, S. H. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Misale, S., Yaeger, R. D., Mezzadra, R., Sinopoli, J. C., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1236956/v1 · Cited by 1
Self-citationAllosteric regulation of switch-II controls K-Ras oncogenicityPreprint
Yang, M. H., Tran, T. H., Hunt, B., Agnor, R., Johnson, C. W., Waybright, T. J., Nowak, J. A., Stephen, A. G., Simanshu, D. K., & Haigis, K. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.20.508702 · Cited by 1
CRISPR prime editing for unconstrained correction of oncogenic KRAS variantsPreprint
Jang, G., Kweon, J., & Kim, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.21.521522 · Cited by 1
Agosile, O. O., Njoku, P. C., Oduwe, U., Aremu, A. J., Fajobi, S. J., Akachukwu, S. O., Adebisi, A. R., Abolaji, A. O., & Omirin, E. S. (2023) · Research Square · doi:10.21203/rs.3.rs-3079675/v1 · Cited by 1
Metadata
- Authors
- Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Wellspring Biosciences (United States) (US)
- Corresponding author
- Lito, Piro
- Rosen, Neal
- Venue
- Science
- Published
- 2016-02-05
- Volume
- 351
- Issue
- 6273
- Pages
- 604-608
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4955282
- OpenAlex
- W2233032895
- Semantic Scholar
- e165d3c03cf60d1cdc247a235e53363d62727803
- Cited by
- 691
- References
- 38
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 69 · 2023: 75 · 2022: 86 · 2021: 92 · 2020: 71 · 2019: 58 · 2018: 47 · 2017: 49 · 2016: 29
- FWCI
- 31.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (P01CA129243-06, K08CA191082-01A1)
- Memorial Sloan Kettering Cancer Center Experimental Therapeutics (SKI12103)
- LUNGevity Foundation Career Development Award
- V Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, GTPase activity, nucleotide exchange, KRAS-driven cancers, tyrosine kinase signaling, tumor cell growth inhibition
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Alleles, Antineoplastic Agents, Azetidines, Cysteine, Cytidine Diphosphate, Enzyme Inhibitors, Glycine, Guanosine Triphosphate, Humans, Lung Neoplasms, Mutation, Piperazines, Protein Conformation, Time Factors, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, HEK293 Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
